GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NurExone Biologic Inc (TSXV:NRX) » Definitions » Net Margin %

NurExone Biologic (TSXV:NRX) Net Margin % : 0.00% (As of Sep. 2024)


View and export this data going back to 2022. Start your Free Trial

What is NurExone Biologic Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. NurExone Biologic's Net Income for the three months ended in Sep. 2024 was C$-1.69 Mil. NurExone Biologic's Revenue for the three months ended in Sep. 2024 was C$0.00 Mil. Therefore, NurExone Biologic's net margin for the quarter that ended in Sep. 2024 was 0.00%.

The historical rank and industry rank for NurExone Biologic's Net Margin % or its related term are showing as below:


TSXV:NRX's Net Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -132.46
* Ranked among companies with meaningful Net Margin % only.

NurExone Biologic Net Margin % Historical Data

The historical data trend for NurExone Biologic's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NurExone Biologic Net Margin % Chart

NurExone Biologic Annual Data
Trend Dec21 Dec22 Dec23
Net Margin %
- - -

NurExone Biologic Quarterly Data
Mar21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of NurExone Biologic's Net Margin %

For the Biotechnology subindustry, NurExone Biologic's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NurExone Biologic's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NurExone Biologic's Net Margin % distribution charts can be found below:

* The bar in red indicates where NurExone Biologic's Net Margin % falls into.


;
;

NurExone Biologic Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

NurExone Biologic's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin=Net Income (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-4.882/0
= %

NurExone Biologic's Net Margin for the quarter that ended in Sep. 2024 is calculated as

Net Margin=Net Income (Q: Sep. 2024 )/Revenue (Q: Sep. 2024 )
=-1.693/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NurExone Biologic  (TSXV:NRX) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


NurExone Biologic Net Margin % Related Terms

Thank you for viewing the detailed overview of NurExone Biologic's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


NurExone Biologic Business Description

Traded in Other Exchanges
Address
1 Adelaide St. East, Suite 801, Toronto, ON, CAN, M5C 2V9
NurExone Biologic Inc is a company that focuses on developing innovative, biological and minimally invasive treatments for Spinal Cord Injury and Traumatic Brain Injury. Their primary product is ExoTherapy, which is an exosome therapy production platform. The company has two business lines. Firstly, it is developing ExoPTEN, a product that utilizes ExoTherapy for the treatment of acute Spinal Cord Injuries (SCI). Secondly, it aims to monetize its proprietary ExoTherapy technology and production platform by licensing it to the global biopharmaceutical industry for other diseases and indications.
Executives
James Angus Wilson (bilkstys-) Richardson 10% Security Holder, Director, Senior Officer

NurExone Biologic Headlines

No Headlines